News & Events
See the latest news from Tango Biosciences, and check out where we’ll be next!
The Latest
-
Tango Biosciences Appoints Zachary Gurard-Levin, PhD to Board of Directors
Appointment Brings Over Ten Years as a CRO Executive Tango Biosciences, Inc., the premier contract research organization for custom affinity reagents by phage display, announced the appointment of Zachary Gurard-Levin, PhD, to its board of directors effective immediately. Gurard-Levin brings over two decades of experience in assay development and driving successful research programs for biotech…
All News & Events
Sort by Type
-
Event
ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025
Chicago, IL | May 12-15, 2025 Join Tango Biosciences at ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025! Booth CP3 This meeting attracts a highly targeted audience composed of experts and researchers in drug discovery and development. Visit the Tango Biosciences booth to talk to our experts in peptide therapeutics discovery, targeted protein degradation for PROTACs and molecular glues, […]
-
Event
AACR Annual Meeting
Chicago, IL | April 25-30, 2025 Attending the 2025 AACR Annual Meeting? Schedule a meeting with Tango Biosciences experts to talk about your upcoming needs in antibody and affinity reagent discovery! The AACR Annual Meeting is the critical driver of progress against cancer, the place where scientists, clinicians, other health care professionals, survivors, patients, and […]
-
News
Michael Scholle Appointed CEO of Tango Biosciences
Co-founder Brian Kay to assume Chief Scientific Officer, focused on scientific innovation and operations CHICAGO–Tango Biosciences, Inc., the premier research partner for custom affinity reagents by phage display, announced Michael Scholle, MS, MBA as Chief Executive Officer effective immediately. Scholle is one of three co-founders of Tango Biosciences and an active board member. This transition enables president […]
-
Event
SLAS 2025
Visit Tango Biosciences at the 2025 SLAS International Conference & Exhibition! January 25-29, 2025 | San Diego, CA Booth #2317 Plus, mark your calendar to join our Solution Spotlight presentation or join us for one of two poster presentations: Solution Spotlight: Rapid Phage Display Solutions ideal for SLAS: Screening Ligands for Affinity and Selectivity Tuesday, […]
-
News
NIH SBIR Award
The National Institutes of Health (NIH) awarded a phase I grant to Tango Biosciences in January 2021. This award will support a collaborative effort that generates recombinant antibodies and antibody-like reagents for 6 SARS-CoV-2 viral proteins. These reagents will aid scientists in understanding the function of these viral proteins inside infected cells. Such information may […]
-
News
Tango Biosciences publishes work on SARS-CoV-2 virus
Tango Biosciences scientists, in collaboration with colleagues from B2S Life Sciences, LifeTein, and Euprotein, publish a scientific report on generating recombinant affinity reagents (monobodies) to the receptor binding domain (RBD) of the SARS-CoV-2 virus, which is responsible for the COVID-19 pandemic. Soluble forms of the monobodies bound to several different preparations of the RBD and […]
-
News
Society for Laboratory Automation & Screening Ignite Award
Tango Biosciences was nominated as a finalist for the best start-up or emerging company. Named “one of the top 8 bioscience start-ups in 2019.”
-
News
NIH STTR award
In April 2018, Tango Biosciences received a R41 award from NIH. The goals of the grant are to generate two-site capable affinity reagents through MegaSTAR to two sets of targets. One set represents biomarkers of colorectal cancer and myocardial infarction. MegaSTAR reagents will be benchmarked against existing commercial sandwich reagents, and the performance metrics (i.e., […]